590 related articles for article (PubMed ID: 24081731)
1. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
Lin TC; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
Lin TC; Lee CH; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
[TBL] [Abstract][Full Text] [Related]
3. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Solomon DH
Ann Intern Med; 2008 May; 148(9):637-46. PubMed ID: 18458276
[TBL] [Abstract][Full Text] [Related]
4. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
Lin TC; Yang CY; Kao Yang YH; Lin SJ
Osteoporos Int; 2014 May; 25(5):1503-11. PubMed ID: 24515577
[TBL] [Abstract][Full Text] [Related]
6. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.
Cheng TT; Yu SF; Hsu CY; Chen SH; Su BY; Yang TS
Clin Ther; 2013 Jul; 35(7):1005-15. PubMed ID: 23831360
[TBL] [Abstract][Full Text] [Related]
7. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
9. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis.
Foster SA; Shi N; Curkendall S; Stock J; Chu BC; Burge R; Diakun DR; Krege JH
BMC Womens Health; 2013 Mar; 13():15. PubMed ID: 23521803
[TBL] [Abstract][Full Text] [Related]
10. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.
Cadarette SM; Solomon DH; Katz JN; Patrick AR; Brookhart MA
Osteoporos Int; 2011 Mar; 22(3):943-54. PubMed ID: 20532481
[TBL] [Abstract][Full Text] [Related]
11. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women.
Hsiao FY; Huang WF; Chen YM; Wen YW; Kao YH; Chen LK; Tsai YW
Clin Ther; 2011 Nov; 33(11):1659-67. PubMed ID: 22018450
[TBL] [Abstract][Full Text] [Related]
12. Prevention and treatment of osteoporosis in women with breast cancer.
Mincey BA; Moraghan TJ; Perez EA
Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
[TBL] [Abstract][Full Text] [Related]
13. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.
Huang WF; Tsai YW; Wen YW; Hsiao FY; Kuo KN; Tsai CR
Menopause; 2010; 17(1):57-63. PubMed ID: 19680161
[TBL] [Abstract][Full Text] [Related]
14. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
15. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.
Kingkaew P; Maleewong U; Ngarmukos C; Teerawattananon Y
Value Health; 2012; 15(1 Suppl):S20-8. PubMed ID: 22265062
[TBL] [Abstract][Full Text] [Related]
16. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
Lu PY; Hsieh CF; Tsai YW; Huang WF
Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
[TBL] [Abstract][Full Text] [Related]
17. Real-world evidence of raloxifene versus alendronate in preventing non-vertebral fractures in Japanese women with osteoporosis: retrospective analysis of a hospital claims database.
Tanaka S; Yamamoto T; Oda E; Nakamura M; Fujiwara S
J Bone Miner Metab; 2018 Jan; 36(1):87-94. PubMed ID: 28028633
[TBL] [Abstract][Full Text] [Related]
18. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.
Karpf DB; Shapiro DR; Seeman E; Ensrud KE; Johnston CC; Adami S; Harris ST; Santora AC; Hirsch LJ; Oppenheimer L; Thompson D
JAMA; 1997 Apr; 277(14):1159-64. PubMed ID: 9087473
[TBL] [Abstract][Full Text] [Related]
19. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
Levis S; Theodore G
J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
